News & Updates

Giving adjuvant S-1 to patients with curatively resected biliary tract cancer (BTC) significantly improves survival compared with observation following surgery, according to the ASCOT trial presented in the 2022 ASCO Gastrointestinal Cancers Symposium (GICS).

Acupuncture seems to be better than pharmacotherapy at relieving emotional symptoms in patients with functional gastrointestinal disorders (FGIDs), reports a recent meta-analysis.

Among inflammatory bowel disease (IBD) patients, the discontinuation of immunomodulator treatment does not contribute to the risk of loss of response although it may lead to an increase in antidrug antibodies, according to a study.

Acid suppression therapy appears to exert no meaningful effect on the efficacy or safety of plecanatide when administered concomitantly, according to a study.

The addition of postoperative radiotherapy (PORT) or postoperative concurrent chemoradiotherapy (POCRT) to surgery led to significant improvements in disease-free survival (DFS) and overall survival (OS) in individuals with pathological stage IIB-III oesophageal squamous cell carcinoma (SCC) compared with surgery alone, a prospective phase III study from China suggests.

The first-in-class sphingosine-1-phosphate receptor modulator ozanimod showed promising efficacy and safety in a relatively treatment-refractory cohort of patients with ulcerative colitis (UC), according to the initial results of a prospective, observational cohort study presented at the Crohn’s and Colitis Congress 2022.

Women with type 1 diabetes present with a shift in the gut mycobiome across pregnancy, and this shift is strongly linked to gut inflammation and impaired intestinal barrier function, as reported in a study.

For treated patients with coeliac disease (CD) who are experiencing persistent symptoms, a short-term diet with moderately low fermentable oligo-, di-, monosaccharides and polyols (FODMAP) helps reduce gastrointestinal symptoms and improve CD-specific health, as suggested in a study.

Treatment with the anti-interleukin-23p19 inhibitor mirikizumab led to significant improvements in patient-assessed disease severity and activity, as well as abdominal pain, in individuals with moderate-to-severe active Crohn’s disease, according to phase II data presented at the Crohn’s and Colitis Congress (CCC) 2022.